Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 1940-1944

  Lacchini, Riccardo ^a   Jacob Ferreira, Anna L B ^a   Luizon, Marcelo R ^b   Coeli, Fernanda B ^a   Izidoro Toledo, Tatiane C ^b   Gasparini, Sandra ^a   Ferreira Sae, Maria C ^a   Schreiber, Roberto ^a   Nadruz, Wilson ^a   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Heart remodeling; Left ventricular hypertrophy; MMP 9 haplotypes; MMP 9 polymorphisms

Indexed keywords

GELATINASE B;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE;

CASE-CONTROL STUDIES; EXONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; HAPLOTYPES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 9; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 77957754348     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.008     Document Type: Article

References (27)

1. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65:45-79.
2. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
3. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
4. Polyakova V., Hein S., Kostin S., Ziegelhoeffer T., Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004, 44:1609-1618.
5. Ahmed S.H., Clark L.L., Pennington W.R., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113:2089-2096.
6. Altieri P., Brunelli C., Garibaldi S., et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003, 33:648-656.
7. Dini F.L., Buralli S., Bajraktari G., et al. Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease. Biomed Pharmacother 2010, 64:339-342.
8. Mizon-Gerard F., de Groote P., Lamblin N., et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 2004, 25:688-693.
9. Castro M.M., Rizzi E., Figueiredo-Lopes L., et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008, 198:320-331.
10. Rizzi E., Castro M.M., Prado C.M., et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010, 16:599-608.
11. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
12. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
13. Demacq C., Vasconcellos V.B., Marcaccini A.M., Gerlach R.F., Machado A.A., Tanus-Santos J.E. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacogenomics J 2009, 9:265-273.
14. Demacq C., Vasconcellos V.B., Marcaccini A.M., Gerlach R.F., Silva W.A., Tanus-Santos J.E. Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 2008, 46:57-63.
15. Zhang B., Ye S., Herrmann S.M., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.
16. Shimajiri S., Arima N., Tanimoto A., et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 1999, 455:70-74.
17. Allan J.A., Docherty A.J., Barker P.J., Huskisson N.S., Reynolds J.J., Murphy G. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 1995, 309(Pt 1):299-306.
18. Yasmin, McEniery C.M., O'Shaughnessy K.M., et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006, 26:1799-1805.
19. Fiotti N., Altamura N., Fisicaro M., et al. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:1330-1336.
20. Vasconcellos V., Lacchini R., Jacob-Ferreira A.L., et al. Endothelial nitric oxide synthase haplotypes associated with hypertension do not predispose to cardiac hypertrophy. DNA Cell Biol 2010, 29:171-176.
21. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006, 7:79-108.
22. Lauer M.S., Anderson K.M., Larson M.G., Levy D. A new method for indexing left ventricular mass for differences in body size. Am J Cardiol 1994, 74:487-491.
23. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002, 70:425-434.
24. Zhou S., Feely J., Spiers J.P., Mahmud A. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens 2007, 21:861-867.
25. Campbell L.G., Ramachandran S., Liu W., et al. Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. Am J Transplant 2005, 5:517-528.
26. Heymans S., Lupu F., Terclavers S., et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 2005, 166:15-25.
27. Demacq C., de Souza A.P., Machado A.A., Gerlach R.F., Tanus-Santos J.E. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 2006, 365:183-187.